Orforglipron: difference between revisions
Diff·revision 9 → 10·13:23, 25 Mar 2025
Difference between revision 9 and revision 10 of Orforglipron. 6 lines changed; the page grew by 109 bytes.
| Revision 9 — 10:32, 5 Mar 2025 MassSpecMarv (talk) fix the anchor on an internal link 4,056 bytes +719 | Revision 10 — 13:23, 25 Mar 2025 Chromatokid (talk) expand §Reported clinical findings 4,165 bytes +109 | ||
|---|---|---|---|
| 40 | <ref name="graaf2016">de Graaf C, Donnelly D, Wootten D, et al. "Glucagon-like peptide-1 and its class B G protein-coupled receptors." ''Pharmacological Reviews'' 68(4):954–1013 (2016). PMID 27630114.</ref> | 40 | <ref name="graaf2016">de Graaf C, Donnelly D, Wootten D, et al. "Glucagon-like peptide-1 and its class B G protein-coupled receptors." ''Pharmacological Reviews'' 68(4):954–1013 (2016). PMID 27630114.</ref> |
| 41 | 41 | ||
| + | 42 | == See also == | |
| + | 43 | * [[GLP-1 receptor agonist]] | |
| + | 44 | * [[Oral semaglutide]] | |
| + | 45 | * [[GLP-1 receptor]] | |
| + | 46 | * [[Receptor bias]] | |
| + | 47 | ||
| 42 | {{DEFAULTSORT:Orforglipron}} | 48 | {{DEFAULTSORT:Orforglipron}} |
| 43 | [[Category:Small-molecule incretin agonists]] | 49 | [[Category:Small-molecule incretin agonists]] |